McGill researchers pooled data on 25,816 adults. Amycretin reached about 23.9% placebo-subtracted loss and retatrutide about 22.1%, though trials differed.
Recap by typeshit. Full story at Healthgrades.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Remote visits and easier contact with providers are lowering some of the hurdles to beginning and sticking with GLP-1 care.
The UK firm says it climbed from 3,048th in July on Lilly's supply rankings, with repeat orders now over 30% of revenue and a 14,000-a-day fulfilment line coming.
Loading…